Search

Your search keyword '"Augustin, Hellmut G."' showing total 858 results

Search Constraints

Start Over You searched for: Author "Augustin, Hellmut G." Remove constraint Author: "Augustin, Hellmut G."
858 results on '"Augustin, Hellmut G."'

Search Results

2. The angiopoietin receptor Tie2 is atheroprotective in arterial endothelium

3. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling

5. A systems view of the vascular endothelium in health and disease.

6. Consensus guidelines for the use and interpretation of angiogenesis assays

7. LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency

9. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

12. Lymphangiogenesis requires Ang2/Tie/PI3K signaling for VEGFR3 cell-surface expression

13. Caspase-8 modulates physiological and pathological angiogenesis during retina development

14. A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain

15. State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization

17. Author Correction: Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

18. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

19. MicroRNA-10 Regulates the Angiogenic Behavior of Zebrafish and Human Endothelial Cells by Promoting Vascular Endothelial Growth Factor Signaling

24. Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization

25. Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization

26. Supplementary Table 1, Figures 1-3 from EphB4 Promotes Site-Specific Metastatic Tumor Cell Dissemination by Interacting with Endothelial Cell–Expressed EphrinB2

27. Supplementary Figures from Timed Ang2-Targeted Therapy Identifies the Angiopoietin–Tie Pathway as Key Regulator of Fatal Lymphogenous Metastasis

28. Data from Timed Ang2-Targeted Therapy Identifies the Angiopoietin–Tie Pathway as Key Regulator of Fatal Lymphogenous Metastasis

29. Supplementary Table from Timed Ang2-Targeted Therapy Identifies the Angiopoietin–Tie Pathway as Key Regulator of Fatal Lymphogenous Metastasis

30. Primary tumor-derived systemic nANGPTL4 inhibits metastasis

32. Endothelial Tie1-mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis

34. Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma

39. Supplementary Figure 4 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

40. Supplementary Data from VEGFR1+ Metastasis–Associated Macrophages Contribute to Metastatic Angiogenesis and Influence Colorectal Cancer Patient Outcome

41. Data from Tumor Cell–Derived Angiopoietin-2 Promotes Metastasis in Melanoma

42. Supplementary Figure 7 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

43. Supplementary Figure 5 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

44. Supplementary Table 1 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

45. Supplementary Figure 3 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

46. Supplementary Data from Tumor Cell–Derived Angiopoietin-2 Promotes Metastasis in Melanoma

47. Supplementary Figure 6 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

48. Supplementary Material from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

49. Supplementary Figure 2 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Catalog

Books, media, physical & digital resources